Catalog No.
DGK09701
Expression system
Mammalian Cells
Species reactivity
General
Host species
Humanized
Isotype
Fab-G1-kappa
Clonality
Monoclonal
Target
Dabigatran Etexilate Mesylate
Concentration
0.56 mg/ml
Endotoxin level
Please contact with the lab for this information.
Purity
>95% as determined by SDS-PAGE.
Purification
Protein A/G purified from cell culture supernatant.
Accession
CAS: 211915-06-9
Applications
Research Grade Biosimilar
Form
Liquid
Storage buffer
0.01M PBS, pH 7.4.
Stability and Storage
Use a manual defrost freezer and avoid repeated freeze-thaw cycles. Store at 4°C short term (1-2 weeks). Store at -20°C 12 months. Store at -80°C long term.
Alternative Names
aDabi-Fab, anti-dabigatran, antidote for dabigatran, CAS: 1362509-93-0
Clone ID
Idarucizumab
Idarucizumab: What Should We Know?, PMID: 28950812
Idarucizumab for Dabigatran Reversal, PMID: 26095746
Idarucizumab for Dabigatran Reversal - Full Cohort Analysis, PMID: 28693366
Idarucizumab, PMID: 27789932
Idarucizumab for the Reversal of Dabigatran, PMID: 28110992
Idarucizumab, PMID: 29999814
Idarucizumab for Reversing Dabigatran-Induced Anticoagulation: A Systematic Review, PMID: 27175894
idarucizumab (PRAXBIND°). Don't rely too heavily on this dabigatran antidote, PMID: 30715821
Idarucizumab: A Review as a Reversal Agent for Dabigatran, PMID: 27388764
Idarucizumab for Reversal of Dabigatran-Associated Anticoagulation, PMID: 27389324
Idarucizumab (Praxbind) Formulary Review, PMID: 27465000
Idarucizumab for Dabigatran-Related Gastrointestinal Bleeds, PMID: 30715945
Idarucizumab for Reversal of Dabigatran: Single-Center Real-World Experience, PMID: 30203330
2019 AHA/ACC/HRS Focused Update of the 2014 AHA/ACC/HRS Guideline for the Management of Patients With Atrial Fibrillation: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Rhythm Society in Collaboration With the Society of Thoracic Surgeons, PMID: 30686041
Idarucizumab: First Global Approval, PMID: 26578027
Spotlight on idarucizumab and its potential for the reversal of anticoagulant effects of dabigatran, PMID: 27274201
Idarucizumab Reverses Dabigatran Anticoagulant Activity in Healthy Chinese Volunteers: A Pharmacokinetics, Pharmacodynamics, and Safety Study, PMID: 32691242
Evidence supporting idarucizumab for the reversal of dabigatran, PMID: 27697436
Evidence Supporting Idarucizumab for the Reversal of Dabigatran, PMID: 27568285
Idarucizumab for dabigatran reversal in daily clinical practice: A case series, PMID: 32175987
Reversal of dabigatran by idarucizumab: when and how?, PMID: 27166653
Idarucizumab before reperfusion therapy in stroke patients on dabigatran: No more cold sweat, PMID: 32079736
Dabigatran reversal with idarucizumab prior to lung transplantation, PMID: 33150658
Assessment of patients post reversal with idarucizumab, PMID: 30120649
[Experience with idarucizumab as a reverse agent of dabigatran], PMID: 32841148
Use of idarucizumab in reversing dabigatran anticoagulant effect: a critical appraisal, PMID: 30174430
Reversal of direct oral anticoagulants: Guidance from the Anticoagulation Forum, PMID: 30916798
Idarucizumab for Reversion of Anticoagulant Effect in Daily Practice, PMID: 31470446
Three-month use of idarucizumab at Christchurch Hospital through the emergency department and MedChartTM, PMID: 31352470
Idarucizumab: The Antidote for Reversal of Dabigatran, PMID: 26700008
Idarucizumab (Praxbind)--an antidote for dabigatran, PMID: 26583604
Idarucizumab for Reversal of Dabigatran in Early/Emergency Surgeries: A Case Series, PMID: 31662218
2019 AHA/ACC/HRS Focused Update of the 2014 AHA/ACC/HRS Guideline for the Management of Patients With Atrial Fibrillation: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Rhythm Society, PMID: 30703431
Idarucizumab, a Humanized, Monoclonal Antibody Fragment for Immediate Reversal of Dabigatran, PMID: 26894245
Idarucizumab for Dabigatran Reversal in the Management of Patients With Gastrointestinal Bleeding, PMID: 30586692
Global Use of Idarucizumab in Clinical Practice: Outcomes of the RE-VECTO Surveillance Program, PMID: 31470445
Real-world experience with reversal of dabigatran by idarucizumab, PMID: 33227654
Dabigatran Reversal With Idarucizumab in Patients With Renal Impairment, PMID: 31582135
Stroke reperfusion therapy following dabigatran reversal with idarucizumab in a national cohort, PMID: 32079737
Idarucizumab for Emergency Reversal of Anticoagulant Effects of Dabigatran: Interim Results of a Japanese Post-Marketing Surveillance Study, PMID: 32152956
Anticoagulation Reversal, PMID: 30037445
Idarucizumab in the 'real world': possibilities and limitations, PMID: 30364967
Idarucizumab, a specific reversal agent for dabigatran: mode of action, pharmacokinetics and pharmacodynamics, and safety and efficacy in phase 1 subjects, PMID: 27707528
Performance of idarucizumab as antidote of dabigatran in daily clinical practice, PMID: 30339226
Real World Outcomes Associated with Idarucizumab: Population-Based Retrospective Cohort Study, PMID: 31332727
Idarucizumab and Factor Xa Reversal Agents: Role in Hospital Guidelines and Protocols, PMID: 27569673
Pharmacokinetics of idarucizumab and its target dabigatran in patients requiring urgent reversal of the anticoagulant effect of dabigatran, PMID: 31050868
Drugs for atrial fibrillation, PMID: 31599871
Idarucizumab: Clinical Role of a Novel Reversal Agent for Dabigatran, PMID: 27477871
Idarucizumab and factor Xa reversal agents: role in hospital guidelines and protocols, PMID: 27697438
For research use only. Not for human or drug use.
